WO2018227448A1 - 口服毒物吸附剂及其制造方法 - Google Patents

口服毒物吸附剂及其制造方法 Download PDF

Info

Publication number
WO2018227448A1
WO2018227448A1 PCT/CN2017/088373 CN2017088373W WO2018227448A1 WO 2018227448 A1 WO2018227448 A1 WO 2018227448A1 CN 2017088373 W CN2017088373 W CN 2017088373W WO 2018227448 A1 WO2018227448 A1 WO 2018227448A1
Authority
WO
WIPO (PCT)
Prior art keywords
bamboo charcoal
oral
bamboo
polymer material
active
Prior art date
Application number
PCT/CN2017/088373
Other languages
English (en)
French (fr)
Inventor
林峯辉
吴宛霖
黄建元
陈昱宏
Original Assignee
财团法人祺华教育基金会
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 财团法人祺华教育基金会 filed Critical 财团法人祺华教育基金会
Priority to PCT/CN2017/088373 priority Critical patent/WO2018227448A1/zh
Publication of WO2018227448A1 publication Critical patent/WO2018227448A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/20—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbon; comprising carbon obtained by carbonising processes

Definitions

  • Oral poison adsorbent and method for producing same
  • the present invention relates to an active bamboo charcoal microsphere having a porous structure, and more particularly to an oral poison adsorbent capable of efficiently adsorbing nephrotoxin in the digestive tract and rapidly excreting through the gastrointestinal tract and a method for producing the same.
  • nephrotoxin and heavy metal ions enter the human body through the gastrointestinal tract, respiratory tract and skin, and further bond with proteins in the body. It is transported to the kidney for filtration and removal, so nephrotoxin and heavy metal ions are easily accumulated in the kidney glomerulus and renal tubules, causing kidney damage, which in turn reduces renal function, and finally evolves into chronic kidney disease; patients with chronic kidney disease lose kidney function The waste produced by the body cannot be excreted from the body, gradually accumulate in the body, causing toxicity of various organs.
  • kidney toxins are metabolized by dialysis, but many kidney toxins, including heavy metals, are still exposed to daily life of dialysis patients. Ions, phosphates, and urinary toxins can cause further damage to the kidneys. Therefore, if an oral agent can be used to excrete nephrotoxin, it will benefit the kidney patients and take care of modern times. Human health.
  • Urine toxins include medium molecular urinary toxins, low molecular urea toxins, and macromolecular toxins.
  • the production of urinary toxins is mainly a protein ingested by humans, which is converted into a precursor of urinary toxin by metabolism of bacteria, and is absorbed by the large intestine. After being converted into urinary toxins in the human body, the accumulation of urinary toxins in the body can cause chronic kidney disease. For patients with chronic kidney disease, the accumulation of urinary toxins in the body can cause cardiovascular disease, worsen chronic kidney disease and other complications. Symptoms; urinary toxins are indoxyl
  • dialysis the most common way for toxic substances to be excreted in vitro is to perform hemodialysis, commonly known as "dialysis".
  • dialysis the urinary toxins and water are excreted to reduce the symptoms of uremia and stabilize vital signs.
  • Hemodialysis Although it has a good ability to filter waste, it has a poor effect on pro-protein urinary toxins, and hemodialysis relies on the expertise of medical personnel in operation, and the dialysis process is lengthy and expensive, and is used in dialysis treatment. After treatment, there may be cramps, nausea, fatigue, etc., and each treatment has blood loss or blood cell damage, which is prone to anemia and other symptoms, resulting in physical and mental stress.
  • the inventors have developed an oral toxic adsorbent that is orally administered into the body to adsorb heavy metals, urinary toxins, and phosphorus, and has good adsorptivity and rapid excretion to solve the current problem.
  • the object of the present invention is to provide an oral toxicant adsorbent which can be administered orally to enter the gastrointestinal tract to adsorb organic or inorganic toxicants, including: heavy metals, phosphorus, urinary toxins, molecules affecting liver and kidney function, errors Eat poisons or pathogens, and can be quickly excreted from the body, not in the gastrointestinal tract; so, not only can be used in healthy people and chronic kidney disease patients in the daily life of toxic substances, but also in the emergency of chemical poisoning patients Therapeutic drugs are administered to slow the spread of poisons in the body.
  • organic or inorganic toxicants including: heavy metals, phosphorus, urinary toxins, molecules affecting liver and kidney function, errors Eat poisons or pathogens, and can be quickly excreted from the body, not in the gastrointestinal tract; so, not only can be used in healthy people and chronic kidney disease patients in the daily life of toxic substances, but also in the emergency of chemical poisoning patients Therapeutic drugs are administered to slow the spread of poisons in the body.
  • the present invention selects a porous and adsorbable bamboo charcoal for the manufacture of an oral adsorbent, which is prepared by: first cutting a bamboo material, and then cleaning it into a high-temperature carbonization furnace; The carbonization furnace is heated to 400 00. C to 950. C, a carbonization process is carried out, and an inert gas is introduced into the carbonization process; then the temperature is maintained at 750 in the high temperature carbonization furnace. C to 1000.
  • bamboo charcoal activation and adding during the activation process Injecting an activator to produce an activated bamboo charcoal; cooling, cleaning and drying the activated bamboo charcoal; grinding the activated bamboo charcoal into an active bamboo charcoal powder, and then mixing the active bamboo charcoal powder with a biodegradable polymer material, Further, the active bamboo charcoal powder mixed with the biodegradable polymer material is dropped into a 0. 101-10% cross-linking solution, thereby preparing an activity for coating the bio-deuterated polymer material with a large amount of active bamboo charcoal powder.
  • bamboo charcoal microspheres, the active bamboo charcoal microspheres are the oral poison adsorbents of the present invention.
  • Another object of the present invention is to prevent the existing oral drug from sticking in the gastrointestinal tract, and the active bamboo charcoal powder is mixed with the natural high molecular substance of the biodegradable polymer material during the preparation process, thereby adsorbing the toxin
  • the oral toxic adsorbent can quickly pass through the gastrointestinal tract and excrete from the body to avoid visceral adhesion, and the surface of the biodegradable polymer material has a plurality of pores, which can enhance the adsorption capacity of the oral toxic adsorbent.
  • the present invention provides an oral toxicant adsorbent which is an active bamboo charcoal microsphere formed by coating a bio-deuterated polymer material with an active bamboo charcoal powder.
  • the active bamboo charcoal microspheres have a particle diameter of about 100 to 2000 micrometers.
  • the mixing weight ratio of the active bamboo charcoal powder to the biodegradable polymer material is 1:2 to 1:5.
  • the active bamboo charcoal microspheres are orally administered with toxic substances adsorbing the gastrointestinal tract, and are excreted from the gastrointestinal tract and excreted by the intestinal tract.
  • the inert gas is selected from any one of nitrogen gas or argon gas, and is introduced into the high temperature carbonization furnace at a rate of from 100 ml/min to 400 ml/min.
  • the activator is selected from any one of carbon dioxide or water vapor, and is introduced into the high temperature carbonization furnace at a rate of from 100 ml/min to 400 ml/m in.
  • the mixing weight ratio of the active bamboo charcoal powder to the biodegradable polymer material is 1:2 to 1:5.
  • the biodegradable polymer material is selected from the group consisting of chitosan, alginic acid, corn starch, methyl cellulose, gelatin, alginate, polydextrin, and the like, any natural polymer, natural polymer improvement, and any A group of synthetic polymers in a single or arbitrary composition.
  • the biodegradable polymer material is alginic acid and chitosan
  • the weight ratio of alginic acid or chitosan to bamboo charcoal powder is 2:1 to 5:1.
  • the beneficial effects of the invention are as follows: the raw material is easy to obtain, the preparation process is simple, and the function of adsorbing toxins of the gastrointestinal tract and rapid excretion is provided.
  • FIG. 1 is a block diagram of a manufacturing process of the present invention
  • FIG. 3 is a scanning electron microscope (SEM) image of the present invention (27x);
  • FIG. 4 is a scanning electron microscope (SEM) image of the present invention (350x);
  • FIG. 5A-5B are comparison diagrams of X-ray diffraction of the present invention.
  • FIG. 6 is a schematic view showing the results of adsorbing ability of an aqueous solution of methylene blue according to the present invention.
  • FIG. 7 is a schematic view showing the results of the adsorption capacity of an aqueous solution of iodine according to the present invention.
  • Figure 8 is an electron microscope (SEM) image of a positively charged bamboo charcoal microsphere of the present invention (30X);
  • Figure 9 is an electron microscope (SEM) image of a negatively charged bamboo charcoal microsphere of the present invention (65X);
  • Embodiment 3 of the present invention is a schematic flow chart of Embodiment 3 of the present invention.
  • 11A is a result of adsorption of heavy metal lead according to Example 3 of the present invention.
  • 11B is a result of adsorption of heavy metal chromium according to Example 3 of the present invention.
  • Example 11C is a phosphate adsorption result of Example 3 of the present invention.
  • 11D is a urinary toxin hydrazine adsorption result according to Example 3 of the present invention.
  • 11E is a result of adsorption of urinary toxin to cresol according to Example 3 of the present invention.
  • the present invention provides an oral toxic adsorbent and a method for producing the same, which are carried out according to the following steps:
  • a bamboo material 501 is cut into a size of about 10 cm x 5 cm, cleaned and placed in a high temperature carbonization furnace 101, and subjected to step S1, vacuum evacuation; then, step S2 is performed, and the high temperature carbonization furnace 101 is The temperature is 5-20.
  • the heating rate of c /min is raised to 400 to 950. C, where, to 600. c to 900. c is optimal, the cut bamboo 501 is placed therein for 30 to 60 minutes, the bamboo 501 is carbonized, and an inert gas 103 is introduced into the high temperature carbonization furnace at a speed of 100 ml/min to 400 ml/min during the heating process.
  • the inert gas 103 may be nitrogen or argon, and the bamboo 501 is burned and carbonized in an oxygen-free environment to produce a carbonized bamboo 503; then, step S3 is performed.
  • the carbonized bamboo 503 is activated at a high temperature, and the temperature of the high temperature carbonization furnace 101 is maintained at 750 to 1,000.
  • step S4 the active bamboo charcoal 505 is cooled, cleaned and dried with a cleaning solution 502; and step S5 is utilized.
  • Step S6 the polished activated bamboo charcoal powder 507 is mixed with a biodegradable polymer material 102, and the weight ratio thereof is 1. 2-1: 5, preferably 1:3, the activated carbon powder 507 is uniformly dispersed in the biodegradable polymer material 102 by stirring, and the activity of the biodegradable polymer material 102 is further mixed.
  • the bamboo charcoal powder 507 is dropped into 0.01-10% of the cross-linking solution, and the cross-linking solution of the present invention is a 1 M NaOH solution, that is, an active bamboo charcoal having a structure in which the bio-degradable polymer material 102 is coated with a large amount of active bamboo charcoal powder 507 is prepared.
  • the microspheres 509, the active bamboo charcoal microspheres 509 are the oral poison adsorbents of the present invention, and the active bamboo charcoal microspheres 509 have a diameter of about 100 micrometers to 2000 micrometers (see FIG. 2).
  • the bamboo material 501 may be a group of any kind of bamboo such as Mengzongzhu, Fengweizhu or Danzhu of a mature group, and the invention is selected from Mengzong bamboo of four or more years;
  • the cleaning liquid 502 may be an acidic aqueous solution. , an alkaline aqueous solution, an organic solvent, etc.;
  • the biodegradable polymer material 102 can be:
  • W/V chitosan (chito San ), corn starch, methylcellulose, gelatin, alginate, polydextrin and alginate (alginate), any natural polymer, natural polymer modification and any synthesis
  • a polymer any natural polymer, natural polymer modification and any synthesis
  • the active bamboo charcoal microspheres 509 of the present invention are spherical, and the surface morphology of the active bamboo charcoal microspheres 509 is detected by SEM.
  • the SEM image (27x) shows the active bamboo charcoal microspheres.
  • 509 is a complete spherical shape with a rough surface, a size of about 1.5 mm, and an irregular rough hole on the surface.
  • the active bamboo charcoal microsphere 509 is cut, and the SEM image shows (350x) that the active bamboo charcoal microsphere 509 is inside. It is a porous, spongy structure (see Figure 4).
  • the active bamboo charcoal microsphere 509 can pass through the esophagus and can be orally administered into the gastrointestinal tract, and has the characteristics of adsorbing organic or inorganic toxicity in the body.
  • the organic or inorganic toxicity includes: heavy metals, phosphorus, chemicals, bacteria Virus, digestive toxin, other organic waste, objects trapped in the intestine, physiological metabolites, molecules affecting liver and kidney function, and poisons or pathogens that are ingested, the active bamboo charcoal microspheres 509 can adsorb the above substances. Excreted by gastrointestinal motility.
  • the specific surface area analyzer (BET) was used to measure the difference in specific surface area before and after activation of bamboo charcoal. As shown in Table 1, the specific surface area of the activated bamboo charcoal (ie, charred bamboo 503) was 195.82 ⁇ 11.5 mg, when the charred bamboo 503 was 900. At C, after activation by the activator 105, the specific surface area is increased by 2.7 times.
  • the activated activated bamboo charcoal 505 (see FIG. 5A) and the unactivated bamboo charcoal (shown in FIG. 5B) are observed by X-ray diffraction (XRD).
  • XRD X-ray diffraction
  • the crystalline structure, the active bamboo charcoal 505 has no change in crystal structure, microstructure and porosity compared with the unactivated bamboo charcoal, and the activated bamboo charcoal 505 has high porosity and high compared to the unactivated bamboo charcoal through the activation step.
  • the adsorption force and the surface have a functional group, so that the adsorption of the nephrotoxin has a good effect.
  • the inventors conducted an adsorption capacity test of the active bamboo charcoal microspheres 509, such as methylene blue, iodine, metal ions, phosphates, and urinary toxins.
  • the adsorption test of the methylene blue aqueous solution of the oral poison adsorbent is performed.
  • a methylene blue aqueous solution having a concentration of 20 ppm is disposed, 10 mg of the active bamboo charcoal microsphere 509, the unactivated carbonized bamboo 503, and
  • the commercially available oral adsorbent (control group) was immersed in a methylene blue aqueous solution for 24 hours, and then the change in the concentration of the methylene blue aqueous solution was measured using a spectrophotometer; after 24 hours, the active bamboo charcoal microsphere 509 of the present invention was found to have a good effect on methylene blue.
  • Adsorption capacity was performed by the active bamboo charcoal microsphere 509 of the present invention.
  • this embodiment performs the iodine adsorption test of the oral poison adsorbent, and according to the Japanese Industrial Standard JISK1474 (19991), the adsorption of activated carbon on iodine is measured for the detection method of activated carbon, firstly the activity is first bamboo charcoal microspheres 509, unactivated charred bamboo 503, and commercially available oral adsorbent (control group) were added to a standard aqueous solution of iodine for testing, and the amount of iodine adsorbed by the active bamboo charcoal microspheres 509 was measured; the results showed that all three groups were good. The adsorption effect.
  • the active bamboo charcoal powder 507 is tested in Examples 3 and 4 to coat different biodegradable polymer materials 102, and the adsorption capacity of the kidney toxin is tested in a simulated gastrointestinal environment.
  • the nephrotoxin comprises: lead (Pb), chromium (Cr), phosphate (P0 4 3 -), strontium (Indole) and p-cresol (p-Cresol); firstly, these active bamboo charcoal powders 507 are separately mixed
  • the biodegradable polymer material 102 of chitosan is added to form a positively charged positive charcoal microsphere 509' (see Figure 8), and the organism is added with alginate.
  • the polymer material 102 can be deuterated to form a negatively charged negatively charged bamboo charcoal microsphere 509" (see Figure 9). It can be seen from Figures 8 and 9 that the different biodegradable polymer material 102 is coated.
  • the active bamboo charcoal microspheres 509 are still round in shape and have a porous surface morphology.
  • the biodegradable polymer material 102 added with chitosan and alginic acid makes the surface of the active bamboo charcoal microsphere 509 different.
  • the surface of the positively charged bamboo charcoal microsphere 509' of the material 102 has an NH functional group, which can be combined with a negatively charged ion (such as a phosphorus ion), and then combined with a positively charged ion (such as calcium ion) to form a crystal, and Excreted by gastrointestinal motility; and the negatively charged bamboo charcoal microsphere 509" of the biodegradable polymer material 102 coated with alginic acid has a COO-functional group, first with positively charged ions (such as calcium ions) Combined with the negatively charged ions (phosphorus ions), further crystals are formed and excreted by gastrointestinal motility.
  • a negatively charged ion such as a phosphorus ion
  • a positively charged ion such as calcium ion
  • 0.05 g of the positive and negative electric bamboo charcoal microspheres 509' and 509" are respectively taken and immersed in an oral buffer solution B1 containing a rennet toxin T for 5 minutes, respectively.
  • the pH of the buffer solution B 1 is 6.5.
  • the oral buffer solution B1 is taken up, the absorbance is measured, and the amount of the toxin T adsorbed in the oral buffer solution B1 is detected. Then, the kidney toxin T is contained.
  • the gastric juice buffer solution B2 is added to the above-mentioned positive and negative electric bamboo charcoal microspheres 509', 509", and the pH of the gastric juice buffer solution B2 is 2, after soaking for 2 hours, the gastric juice buffer solution B2 is taken out, and the absorbance is tested, and then Adding a small intestinal buffer solution B3 containing the nephrotoxin T to the above-mentioned positive and negative electric bamboo charcoal microspheres 509', 509", the pH of the small intestinal buffer solution B3 is 7.5, and after immersing for 5 hours, the small intestinal buffer is taken out.
  • the absorbance is tested, and finally, the large intestinal buffer solution B4 containing the nephrotoxin T is added to the above-mentioned positive and negative bamboo charcoal microspheres 509', 509", and the pH of the large intestinal buffer solution B4 is 8, After soaking for 24 hours, remove the large intestine Solution B4, measured Try its absorbance.
  • the urine toxin-indole (indole) and p-cresol (p-Cresol) are tested. Since the urinary toxin is only present in the small intestine and the large intestine, 0.05 g of the positive and negative electricity are first introduced. Bamboo charcoal microspheres 509', 509" were soaked in the oral buffer solution B1 for 5 minutes, after 5 minutes, the oral buffer solution B1 was removed, then the gastric juice buffer solution B2 was added and soaked for 2 hours, and the gastric juice buffer was removed after 2 hours.
  • the abscissa is the result of the absorption of these nephrotoxins T by the positive and negatively charged bamboo charcoal microspheres 509', 509" in different buffer solutions, and the ordinate is per gram (g). How many milligrams (mg) of the nephrotoxin T can be absorbed by the positive and negatively charged bamboo charcoal microspheres 509', 509''; among them, the attraction effect of heavy metal lead in the four buffers is statistically significant (see Figure 11A). Show), the attraction effect of heavy metal chromium in the small and large intestine buffers B3 and B4 is statistically significant (see Figure 11B).
  • the attraction effect of phosphate in the oral and gastric buffers Bl and B2 is statistically significant.
  • the attractive effects of sputum in the small, large intestine buffers B3, B4 are statistically significant (see Figure 11D), p-cresol in the small, large intestine buffers B3, B4
  • the attraction effects are statistically significant (see Figure 11E).
  • the positive and negative bamboo charcoal microspheres 509', 509" have good absorption properties for various nephrotoxin T.
  • the active bamboo charcoal microspheres 509 mixed with one or more of the biodegradable polymer materials 102 may be selected and used in combination, wherein the alginic acid is added.
  • the negatively-charged bamboo charcoal microspheres 509 ′ formed by the biodegradable polymer material 102 and the positively-charged bamboo charcoal microspheres 509 ′ formed by the biodegradable polymer material 102 added with chitosan have a mixing ratio of 2 : 1 to 5:1, especially 3:1 is the best, so it can improve the adsorption efficiency.
  • the active bamboo charcoal microspheres 509 can be orally administered into the gastrointestinal tract, because the active bamboo charcoal microspheres 509 have a plurality of pores, and because of activation, the surface has a plurality of functional groups, which can be absorbed into the human body.
  • the toxic substance, and in the production process, the active bamboo charcoal powder 507 is mixed with the biodegradable polymer material 102 of different kinds of natural high molecular substances, so that the active bamboo charcoal microspheres 509 can be quickly excreted through the gastrointestinal tract peristalsis.
  • the raw material of the active bamboo charcoal microsphere 509 is bamboo, and the raw material thereof is easy to obtain, and has been produced.
  • the procedure is simple, and has the function of adsorbing toxins from the gastrointestinal tract and rapidly excreting the body; in contrast, the existing oral adsorption has a complicated production process, is expensive, and is easily adhered to the wall of the gastrointestinal tract after oral administration, and is difficult to move by the gastrointestinal tract. Exhausting the body and many other shortcomings.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种口服毒物吸附剂及其制造方法，其可经口投予，进入体内吸附有机毒或无机毒，包括：重金属、磷以及尿毒素等影响肝肾功能的分子，所涉及的口服毒物吸附剂，不会沾粘在胃肠道，可以快速排出体外；制作步骤包括：将一竹材（501）置于400℃到950℃的温度中，使该竹材（501）炭化，并通入一惰性气体（103）避免竹材氧化，接着在750℃到1000℃温度中通入一活化剂（105），活化该竹材（501），产生一活性竹炭（505），接着将该活性竹炭（505）磨成适当大小并与一生物可蜕化高分子材料（102）混合，即制备出结构为生物可蜕化高分子材料（102）包覆大量活性炭粉末（507）的一活性竹炭微球，该活性竹炭微球即为口服毒物吸附剂。

Description

口服毒物吸附剂及其制造方法 技术领域
[0001] 本发明涉及一种具多孔隙结构的活性竹炭微球， 尤指一种可有效吸附消化道内 的肾毒素， 并可迅速通过肠胃道排出体外的口服毒物吸附剂及其制造方法。 背景技术
[0002] 由于现代人年齢老化、 意外、 疾病以及职业上的长期接触、 环境污染跟日常饮 食， 肾毒素及重金属离子会通过肠胃道、 呼吸道以及皮肤进入到人体， 进一步 与体内蛋白质产生键结， 而被运送至肾脏过滤清除， 因此肾毒素及重金属离子 易堆积在肾丝球以及肾小管， 造成肾脏受损， 进而降低肾功能， 最后演变为慢 性肾脏病； 慢性肾脏病的患者失去肾功能之后， 身体产生的废物无法排出体外 ， 渐渐地累积在体内， 造成各种器官的毒性， 最终需要通过洗肾来将体内毒素 代谢， 可是洗肾患者日常生活中仍会接触到许多肾毒素， 包括重金属离子、 磷 酸盐类以及尿毒素等， 这些肾毒素会对肾脏造成更进一步的破坏， 因此， 若能 幵发一种口服剂， 能将肾毒素排出体外， 将可加惠肾脏病人， 并照顾现代人的 健康。
[0003] 尿毒素包括中分子尿毒素、 低分子尿毒素以及高分子尿毒素， 尿毒素的产生主 要为人类食入的蛋白质， 被细菌代谢后转换为尿毒素的前驱物， 借由大肠吸收 进入人体内后转换为尿毒素， 累积在体内的尿毒素会引起慢性肾脏病， 对慢性 肾脏病患者而言， 不停累积在体内的尿毒素会引发心血管疾病、 使慢性肾脏病 恶化以及其他并发症产生； 尿毒素又以硫酸吲哚酚 (indoxyl
sulfate)以及对甲酚 (p-cresol)在许多文献中被提及， 其累积在身体内会造成许多并 发症， 间接地使肾功能恶化， 最终变成尿毒症。
[0004] 由于慢性肾脏病患者对体内有害物质的排除以及过滤能力有限， 而通过食物进 入人体的磷酸盐， 无法通过肾脏过滤清除， 造成高血磷产生， 进一步避免甲状 腺亢进以及肾性骨病变的发生。
技术问题 [0005] 目前， 毒性物质排出体外最普遍的方式是进行血液透析， 即俗称的"洗肾"， 借 由洗肾将尿毒素、 水分排出体外， 以减轻尿毒症状， 并稳定生命征象， 血液透 析虽然具备了良好的过滤废物的能力， 但是对于亲蛋白质的尿毒素效果不佳， 且血液透析在操作上须仰赖医护人员的专业技术， 并且， 透析过程冗长、 价格 不菲， 在透析治疗中及治疗后， 可能会有抽筋、 恶心、 疲倦感等， 并且， 每次 治疗均有血液流失或血球破坏， 易产生贫血等症状， 导致患者产生身心及经济 上的压力。
[0006] 近年来有人在研发对于慢性肾脏病人吸附体内毒素的口服药物， 现有两种口服 吸附剂， 其原料主要为沥青与植物炭材， 利用沥青制备口服吸附剂吋， 首先需 去除其内所含有的杂质及重金属等物质， 再加工成球状颗粒， 其制备工程繁复 ， 成本高， 因此价格昂贵， 对需长期服用的病人造成经济上的负担； 而借由植 物炭材制备的口服吸附剂， 是将植物炭材研磨成细微粉末， 其难以借由肠胃道 蠕动排出， 而易沾附于肠壁上， 使得吸附毒物的口服药物在体内的停留吋间较 长， 进而刺激肠胃道， 且不利于毒素的排出。
[0007] 因此， 发明人鉴于现有技术的缺点， 幵发一种通过口服， 进入体内吸附重金属 、 尿毒素以及磷， 且具有吸附性良好并快速排出体外的口服毒物吸附剂， 以解 决目前的问题。
问题的解决方案
技术解决方案
[0008] 本发明的目的在于提供一种口服毒物吸附剂， 其可通过口服投予， 进入肠胃道 吸附有机毒或无机毒， 包括： 重金属、 磷、 尿毒素、 影响肝肾功能的分子、 误 食的毒物或致病原等， 并且可以快速排出体外， 不在胃肠道沾粘； 如此， 不但 可应用于健康人以及慢性肾病患者日常生活的毒物排除， 更可应用在化学品中 毒病人的紧急治疗药物投予， 借以减缓毒物在体内的扩散。 为达上述的目的， 本发明选用具多孔性及吸附性的竹炭进行口服吸附剂的制造， 制作方法在于： 先将一竹材裁切， 并清净后放入一高温炭化炉中； 接着将该高温炭化炉升温至 4 00。C至 950。C， 进行炭化程序， 并在炭化过程中通入一惰性气体； 接着持续在该 高温炭化炉中维持其温度在 750。C至 1000。C， 进行竹炭活化， 并在活化过程中加 入一活化剂， 产生一活性竹炭； 将该活性竹炭冷却、 清洗干净并使之干燥； 再 将该活性竹炭研磨成一活性竹炭粉末， 接着将该活性竹炭粉末与一生物可蜕化 高分子材料混合， 进一步将混有该生物可蜕化高分子材料的活性竹炭粉末滴到 0. 01-10%的交联溶液中， 即制备成结构为该生物可蜕化高分子材料包覆大量活性 竹炭粉末的一活性竹炭微球， 该活性竹炭微球即为本发明的口服毒物吸附剂。
[0009] 本发明的另一目的在于避免现有口服药物在肠胃道沾粘的现象产生， 制作过程 中将该活性竹炭粉末混合天然高分子物质的该生物可蜕化高分子材料， 如此吸 附肾毒素的口服毒物吸附剂可快速通过肠胃道并排出体外， 避免肠胃道沾黏， 同吋该生物可蜕化高分子材料的表面具有多个孔洞， 可加强该口服毒物吸附剂 的吸附能力。
[0010] 本发明提供一种口服毒物吸附剂， 其是由一生物可蜕化高分子材料包覆一活性 竹炭粉末所形成的一活性竹炭微球。
[0011] 其中， 该活性竹炭微球的粒径约为 100-2000微米。
[0012] 其中， 该活性竹炭粉末与该生物可蜕化高分子材料的混合重量比为 1:2至 1:5。
[0013] 其中， 该活性竹炭微球经口投予用吸附肠胃道的毒性物质， 通过胃肠道并由肠 道排出体外。
[0014] 其中， 该惰性气体选自氮气或氩气中的任一种， 并以 100ml/min至 400ml/min的 速度通入该高温炭化炉中。
[0015] 其中， 该活化剂选自二氧化碳或水蒸气中的任一种， 并以 100ml/min至 400ml/m in的速度通入该高温炭化炉中。
[0016] 其中， 该活性竹炭粉末与该生物可蜕化高分子材料的混合重量比为 1:2至 1:5。
[0017] 其中， 该生物可蜕化高分子材料选自几丁聚醣、 海藻酸、 玉米淀粉、 甲基纤维 素、 明胶、 褐藻胶、 聚糊精等任何天然高分子、 天然高分子改良及任何合成高 分子单一或任意组成的群组。
[0018] 其中， 该生物可蜕化高分子材料为海藻酸与几丁聚醣， 且其海藻酸或几丁聚醣 与竹炭粉末混合重量比为 2: 1至 5: 1。
发明的有益效果
有益效果 [0019] 本发明的有益效果为： 原料取得容易， 制作过程简单， 具有吸附肠胃道的毒素 与快速排出体外的功能。
对附图的简要说明
附图说明
[0020] 图 1为本发明的制作过程方块流程图；
[0021] 图 2为本发明的剖面结构示意图；
[0022] 图 3为本发明的扫描式电子显微镜 (SEM)影像 (27x);
[0023] 图 4为本发明的扫描式电子显微镜 (SEM)影像 (350x);
[0024] 图 5A-图 5B为本发明的 X射线绕射比较图；
[0025] 图 6为本发明对亚甲基蓝水溶液吸附能力的结果示意图；
[0026] 图 7为本发明对碘水溶液吸附能力的结果示意图；
[0027] 图 8为本发明的带正电竹炭微球的电子显微镜 (SEM)影像 (30X);
[0028] 图 9为本发明的带负电竹炭微球的电子显微镜 (SEM)影像 (65X);
[0029] 图 10为本发明的实施例 3的流程示意图；
[0030] 图 11A为本发明实施例 3的重金属铅吸附结果；
[0031] 图 11B为本发明实施例 3的重金属铬吸附结果；
[0032] 图 11C为本发明实施例 3的磷酸盐吸附结果；
[0033] 图 11D为本发明实施例 3的尿毒素吲哚吸附结果；
[0034] 图 11E为本发明实施例 3的尿毒素对甲酚吸附结果。
[0035] 附图标记说明
[0036] 501 竹材
[0037] 502 清洗液
[0038] 503 炭化竹材
[0039] 505 活性竹炭
[0040] 507 活性竹炭粉末
[0041] 509 活性竹炭微球
[0042] 509， 正电竹炭微球
[0043] 509， '负电竹炭微球 [0044] 101 高温炭化炉
[0045] 102 生物可蜕化高分子材料
[0046] 103 惰性气体
[0047] 105 活化剂
[0048] 107 研磨组件
[0049] S1-S6 少
盖爭
[0050] T 冃母
[0051] Bl 口腔缓冲溶液
[0052] B2 胃液缓冲溶液
[0053] B3 小肠缓冲溶液
[0054] B4 大肠缓冲溶液。
实施该发明的最佳实施例
本发明的最佳实施方式
[0055] 请参阅图 1、 2所示， 本发明提供一种口服毒物吸附剂及其制造方法， 依据下列 步骤流程进行：
[0056] 首先， 将一竹材 501裁切成约 10cm x5cm的大小， 清洗干净后放入一高温炭化 炉 101中， 进行步骤 Sl， 真空抽气； 接着进行步骤 S2， 将该高温炭化炉 101的温 度以 5-20。c /min升温速度升温至 400 至950。C， 其中， 以 600。c至 900。c为最佳 ， 将切割后的该竹材 501置于其中 30至 60分钟， 使该竹材 501炭化， 在升温过程 中以速度 100ml/min至 400ml/min通入一惰性气体 103于该高温炭化炉 101中， 其中 ， 以 lOOml/min的速度为最佳， 该惰性气体 103可为氮气或氩气， 使该竹材 501在 无氧的环境下燃烧炭化， 产生一炭化竹材 503 ; 接着进行步骤 S3， 将该炭化竹材 503在高温下进行活化， 将该高温炭化炉 101的温度维持在 750 至1000。
C， 以 900。c为最佳温度， 并以 lOOml/min至 400ml/min的速度通入一活化剂 105， 进行竹炭活化， 该活化剂 105可为二氧化碳或水蒸气， 通入速度以 lOOml/min为最 佳， 作用吋间为 1至 2小吋， 即可产生一活性竹炭 505 ; 接着进行步骤 S4， 将该活 性竹炭 505冷却， 用一清洗液 502将其清洗干净并使之干燥； 进行步骤 S5， 利用 一研磨组件 107， 将该活性竹炭 505磨成适当大小， 其中， 该研磨组件 107以 100-2 30 mesh为最佳， 分选出 50微米至 1000微米的一活性竹炭粉末 507 ; 进行步骤 S6， 将研磨后的该活性竹炭粉末 507与一生物可蜕化高分子材料 102混和， 其重量比 为 1 : 2-1： 5， 以 1 :3为最佳， 借由搅拌使该活性炭粉末 507均匀分散于该生物可 蜕化高分子材料 102中， 进一步将混有该生物可蜕化高分子材料 102的活性竹炭 粉末 507滴到 0.01- 10%的交联溶液中， 本发明的交联溶液为 lM NaOH溶液， 即制 备出结构为该生物可蜕化高分子材料 102包覆大量活性竹炭粉末 507的一活性竹 炭微球 509， 该活性竹炭微球 509即为本发明的口服毒物吸附剂， 该活性竹炭微 球 509的直径大小约为 100微米至 2000微米 (请参阅图 2所示)。
[0057] 上述制作过程步骤中， 该竹材 501可为成熟群的孟宗竹、 凤尾竹或淡竹等任何 种类竹子的群体， 本发明选自四年生以上的孟宗竹材； 该清洗液 502可为酸性水 溶液、 碱性水溶液以及有机溶剂等； 该生物可蜕化高分子材料 102可为：
(W/V)的几丁聚醣 (chitoSan)、 玉米淀粉、 甲基纤维素、 明胶、 褐藻胶、 聚糊精以 及海藻酸 (alginate)等任何天然高分子、 天然高分子改良及任何合成高分子等单一 或任意组成的群组。
[0058] 请参阅图 3、 4所示， 本发明的该活性竹炭微球 509呈现球状， 以 SEM检测该活 性竹炭微球 509的表面形貌， 该 SEM影像 (27x)显示该活性竹炭微球 509外观为表 面粗糙的完整球型， 大小约 1.5毫米， 且表面呈现不规则的粗糙坑洞， 将该活性 竹炭微球 509剖幵， 其 SEM影像显示 (350x)显示该活性竹炭微球 509内部为多孔隙 类海绵状的结构 (请参阅图 4所示)。
[0059] 该活性竹炭微球 509能通过食道， 可经口投进入肠胃道内， 并具有吸附体内有 机毒或无机毒的特性， 其有机毒或无机毒包括： 重金属、 磷、 化学品、 细菌性 病毒、 消化性毒素、 其他有机性废物、 肠内滞留气体的物体、 生理代谢物、 影 响肝肾功能的分子以及误食的毒物或致病原等， 该活性竹炭微球 509吸附上述物 质后可通过肠胃道蠕动排出体外。
[0060] 使用比表面积分析仪 (BET)测量竹炭活化前后比表面积的差异， 由表一所示， 活化前竹炭 (即炭化竹材 503)的比表面积为 195.82±11.5 m g , 当该炭化竹材 503 在 900。C下， 通入该活化剂 105进行活化后， 其比表面积提高 2.7倍， 为
534.39+32.5 m 2/g。 [0061] 表一、 比表面积
Figure imgf000009_0001
[0062] 请参阅图 5A-图 5B所示， 利用 X射线绕射 (XRD)观察活化的该活性竹炭 505 (请 参阅图 5A所示)以及未活化的竹炭 (请参阅图 5B所示)的结晶结构， 该活性竹炭 505 与未活化的竹炭相比， 其结晶构造、 显微结构以及孔隙度都未改变， 且经活化 步骤， 该活性竹炭 505相较于未活化的竹炭具有高孔隙及高吸附力， 且表面具有 官能基， 如此对肾毒素的吸附具有良好的效果。
[0063] 发明人将该活性竹炭微球 509进行吸附能力测验， 如亚甲基蓝、 碘、 金属离子 、 磷酸盐以及尿毒素等。
[0064] 实施例 1
[0065] 请参阅图 6所示， 本实施例进行该口服毒物吸附剂的亚甲基蓝水溶液吸附测试 ， 首先配置浓度 20ppm的亚甲基蓝水溶液， 将 10mg的该活性竹炭微球 509、 未活 化的炭化竹材 503以及市售口服吸附剂 (对照组)加入亚甲基蓝水溶液中浸泡 24小 吋， 之后使用分光亮度计测量亚甲基蓝水溶液浓度的变化； 24小吋后， 可发现 本发明的该活性竹炭微球 509对亚甲基蓝有良好的吸附能力。
[0066] 实施例 2
[0067] 请参阅图 7所示， 本实施例进行该口服毒物吸附剂的碘吸附测试， 根据日本工 业规范 JISK1474(19991)， 针对活性炭的检测方式进行测量活性炭对碘的吸附， 首先将该活性竹炭微球 509、 未活化的炭化竹材 503以及市售口服吸附剂 (对照组) 加入测试用标准碘水溶液中， 测量碘被该活性竹炭微球 509所吸附量； 其结果显 示三组都有良好的吸附效果。
[0068] 从实施例 1、 2可知本发明具有与市售的口服吸附剂吸附效果相当， 甚至更佳的 吸附力。
[0069] 实施例 3、 4
[0070] 请参阅图 8、 9所示， 在实施例 3、 4中测试该活性竹炭粉末 507包覆不同的该生 物可蜕化高分子材料 102， 在模拟肠胃道环境测试对肾毒素的吸附能力， 其中， 肾毒素包括： 铅 (Pb)、 铬 (Cr)、 磷酸盐 (P0 4 3-)、 吲哚 (Indole)以及对甲酚 (p-Cresol) ； 首先将这些活性竹炭粉末 507分别混合添加几丁聚醣 (Chitosan)的该生物可蜕化 高分子材料 102， 形成带正电的一正电竹炭微球 509' (请参阅 8图所示)， 以及添加 海藻酸 (Alginate)的该生物可蜕化高分子材料 102， 形成带负电的一负电竹炭微球 509" (请参阅 9图所示)， 从第 8以及 9图中可发现， 包覆不同的该生物可蜕化高分 子材料 102的这些活性竹炭微球 509其外形仍为圆形颗粒， 且表面呈现多孔洞的 形貌， 添加几丁聚醣及海藻酸的该生物可蜕化高分子材料 102使该活性竹炭微球 509表面具有不同官能基； 几丁聚醣的该生物可蜕化高分子材料 102的该正电竹 炭微球 509'的表面具有 NH 官能基， 可与带负电的离子结合 (如磷离子)， 接着再 与带正电的离子 (如钙离子)结合后形成结晶， 并通过肠胃道蠕动排出体外； 并且 ， 包覆海藻酸的该生物可蜕化高分子材料 102的该负电竹炭微球 509"的表面具有 COO -官能基， 先与带正电的离子 (如钙离子)结合， 再与带负电的离子 (磷离子)结 合， 进一步形成结晶， 通过肠胃道蠕动排出体外。
[0071] 实施例 3-肾毒素吸附测试 1
[0072] 请参阅图 10所示， 首先， 分别取 0.05g的该正、 负电竹炭微球 509'、 509" , 并分 别浸入含有一肾毒素 T的一口腔缓冲溶液 B1中 5分钟， 该口腔缓冲溶液 B 1的 pH质 为 6.5， 5分钟后吸取该口腔缓冲溶液 Bl， 测其吸光值， 检测该口腔缓冲溶液 B1 中该肾毒素 T被吸附量， 接着， 将含有该肾毒素 T的一胃液缓冲溶液 B2加入上述 的该正、 负电竹炭微球 509'、 509"中， 该胃液缓冲溶液 B2的 pH值为 2， 浸泡 2小 吋后取出该胃液缓冲溶液 B2， 测试其吸光值， 接着， 将含有该肾毒素 T的一小肠 缓冲溶液 B3加入上述的该正、 负电竹炭微球 509'、 509"中， 该小肠缓冲溶液 B3 的 pH值为 7.5， 浸泡 5小吋后取出该小肠缓冲溶液 B3， 测试其吸光值， 最后， 将 含有该肾毒素 T的一大肠缓冲溶液 B4加入上述的该正、 负电竹炭微球 509'、 509" 中， 该大肠缓冲溶液 B4的 pH值为 8， 浸泡 24小吋后取出该大肠缓冲溶液 B4， 测 试其吸光值。
[0073] 在本实施例中， 测试尿毒素 -吲哚 (Indole)以及对甲酚 (p-Cresol)吋， 因尿毒素仅 出现在小肠以及大肠中， 因此先将 0.05g的该正、 负电竹炭微球 509'、 509"浸泡 在该口腔缓冲溶液 B1中 5分钟， 5分钟后去除该口腔缓冲溶液 Bl， 接着加入该胃 液缓冲溶液 B2并浸泡 2小吋， 2小吋后去除该胃液缓冲溶液 B2， 接着加入含有该 肾毒素 T的该小肠缓冲溶液 B3， 浸泡 5小吋后取出该小肠缓冲溶液 B3， 测试其吸 光值， 最后加入含有该肾毒素 T的大肠缓冲溶液 B4于上述该正、 负电竹炭微球 50 9'、 509"中， 浸泡 24小吋后取出该大肠缓冲溶液 B4， 测试其吸光值。
[0074] 请参阅图 11A-11E所示， 横坐标为该正、 负电竹炭微球 509'、 509"分别于不同 缓冲溶液中吸收这些肾毒素 T的结果， 而纵坐标为每公克 (g)的该正、 负电竹炭微 球 509'、 509' '所能吸收多少毫克 (mg)的该肾毒素 T; 其中， 重金属铅在 4种缓冲 液的吸引效果都具有统计意义 (请参阅图 11A所示)， 重金属铬在该小、 大肠缓冲 液 B3、 B4的吸引效果都具有统计意义 (请参阅图 11B所示)， 磷酸盐在该口腔、 胃 缓冲液 Bl、 B2的吸引效果都具有统计意义 (请参阅图 11C所示)， 吲哚在该小、 大 肠缓冲液 B3、 B4的吸引效果都具有统计意义 (请参阅图 11D所示)， 对甲酚在该小 、 大肠缓冲液 B3、 B4的吸引效果都具有统计意义 (请参阅图 11E所示)， 综上所述 ， 该正、 负电竹炭微球 509'、 509"对于各种该肾毒素 T都有良好的吸收功效。
[0075] 为达到良好吸附该肾毒素 T功效， 可选自以一种或多种该生物可蜕化高分子材 料 102混合的该活性竹炭微球 509， 混合搭配使用， 其中， 添加海藻酸的该生物 可蜕化高分子材料 102所形成的该负电竹炭微球 509"与添加几丁聚醣的该生物可 蜕化高分子材料 102所形成的该正电竹炭微球 509'， 其混合使用比例为 2:1至 5:1， 尤以 3:1为最佳， 如此可提升吸附功效。
工业实用性
[0076] 综上所述， 该活性竹炭微球 509可经口投进入肠胃道内， 因该活性竹炭微球 509 具有多数孔洞， 且因受过活化， 其表面具有多种官能基， 可吸收人体内的毒性 物质， 并且， 在制作过程吋该活性竹炭粉末 507混合不同种类的天然高分子物质 的该生物可蜕化高分子材料 102， 使该活性竹炭微球 509可通过肠胃道的蠕动迅 速排出体外， 并且该活性竹炭微球 509的原料为竹子， 其原料取得容易， 制作过 程简单， 并且具有吸附肠胃道的毒素与快速排出体外的功能； 反观现有的口服 吸附具有制作过程繁琐， 价格昂贵， 且口服后易沾附于肠胃道壁上， 难以借由 肠胃道的蠕动排出体外等诸多缺点。
上述详细说明是针对本发明的可行实施例的具体说明， 但是， 该实施例并非用 以限制本发明的专利保护范围， 凡未脱离本发明技艺精神所作的等效实施或变 更， 均应包含于本案的专利范围中。

Claims

权利要求书
[权利要求 1] 一种口服毒物吸附剂， 其特征在于： 其是由一生物可蜕化高分子材料 包覆一活性竹炭粉末所形成的一活性竹炭微球。
[权利要求 2] 如权利要求 1所述的该口服毒物吸附剂， 其特征在于， 该活性竹炭微 球的粒径为 100-2000微米。
[权利要求 3] 如权利要求 1所述的该口服毒物吸附剂， 其特征在于， 该活性竹炭粉 末与该生物可蜕化高分子材料的混合重量比为 1:2至 1:5。
[权利要求 4] 如权利要求 1所述的该口服毒物吸附剂， 其特征在于， 该活性竹炭微 球经口投予用吸附肠胃道的毒性物质， 通过胃肠道并由肠道排出体外
[权利要求 5] —种口服毒物吸附剂的制造方法， 其特征在于， 其步骤包括：
将一竹材裁切后放入一高温炭化炉中， 真空抽气； 将该竹材置于该高温炭化炉中， 并升温至 400。C至 950。C， 反应 30分 钟至 1小吋， 使该竹材炭化， 并在炭化过程中通入一惰性气体， 使该 竹材在无氧的环境下燃烧， 产生一炭化竹材；
将该炭化竹材持续置于该高温炭化炉中， 将该高温炭化炉的温度调整 在 750。C至 1000。C进行活性化， 并在活性化过程中通入一活化剂， 反 应 1至 2小吋， 进行竹炭活化， 产生一活性竹炭； 将该活化竹炭冷却， 再用一清洗液清洗并使之干燥；
将该活性竹炭通过一研磨组件， 形成一 50微米至 1000微米的一活性竹 炭粉末；
将研磨后的该活性竹炭粉末与一生物可蜕化高分子材料混和； 以及 将混有该生物可蜕化高分子材料的活性竹炭粉末滴到 0.01-10%的交 联溶液中， 即制备出直径大小 100微米至 2000微米一活性竹炭微球， 即为口服毒物吸附剂。
[权利要求 6] 如权利要求 5所述的口服毒物吸附剂制作方法， 其特征在于， 该惰性 气体选自氮气或氩气中的任一种， 并以 lOOml/min至 400ml/min的速度 通入该高温炭化炉中。
[权利要求 7] 如权利要求 5所述的口服毒物吸附剂制作方法， 其特征在于， 该活化 剂选自二氧化碳或水蒸气中的任一种， 并以 lOOml/min至 400ml/min的 速度通入该高温炭化炉中。
[权利要求 8] 如权利要求 5所述的口服毒物吸附剂制作方法， 其特征在于， 该活性 竹炭粉末与该生物可蜕化高分子材料的混合重量比为 1:2至 1:5。
[权利要求 9] 如权利要求 8所述的口服毒物吸附剂制作方法， 其特征在于， 该生物 可蜕化高分子材料选自几丁聚醣、 海藻酸、 玉米淀粉、 甲基纤维素、 明胶、 褐藻胶、 聚糊精等任何天然高分子、 天然高分子改良及任何合 成高分子单一或任意组成的群组。
[权利要求 10] 如权利要求 9所述的口服毒物吸附剂制作方法， 其特征在于， 该生物 可蜕化高分子材料为海藻酸与几丁聚醣， 且其海藻酸或几丁聚醣与竹
PCT/CN2017/088373 2017-06-15 2017-06-15 口服毒物吸附剂及其制造方法 WO2018227448A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/088373 WO2018227448A1 (zh) 2017-06-15 2017-06-15 口服毒物吸附剂及其制造方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/088373 WO2018227448A1 (zh) 2017-06-15 2017-06-15 口服毒物吸附剂及其制造方法

Publications (1)

Publication Number Publication Date
WO2018227448A1 true WO2018227448A1 (zh) 2018-12-20

Family

ID=64658847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/088373 WO2018227448A1 (zh) 2017-06-15 2017-06-15 口服毒物吸附剂及其制造方法

Country Status (1)

Country Link
WO (1) WO2018227448A1 (zh)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229367A (zh) * 1996-07-22 1999-09-22 亘起物产有限会社 新的吸附剂
CN101209408A (zh) * 2006-12-25 2008-07-02 丁庆 高效解毒保健活性炭
CN103693642A (zh) * 2013-12-23 2014-04-02 湖南华银能源技术有限公司 制备竹基活性炭的方法及其生产装置
CN105326858A (zh) * 2014-08-12 2016-02-17 无锡成博科技发展有限公司 一种口服给与用吸附剂及其制备方法和应用
CN106238023A (zh) * 2016-08-22 2016-12-21 成都欧赛医疗器械有限公司 一种用于改善血液净化材料表面生物相容性的包膜方法
US20170143763A1 (en) * 2013-02-22 2017-05-25 Kureha Corporation Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1229367A (zh) * 1996-07-22 1999-09-22 亘起物产有限会社 新的吸附剂
CN101209408A (zh) * 2006-12-25 2008-07-02 丁庆 高效解毒保健活性炭
US20170143763A1 (en) * 2013-02-22 2017-05-25 Kureha Corporation Orally administered adsorbent, therapeutic agent for renal disease, and therapeutic agent for liver disease
CN103693642A (zh) * 2013-12-23 2014-04-02 湖南华银能源技术有限公司 制备竹基活性炭的方法及其生产装置
CN105326858A (zh) * 2014-08-12 2016-02-17 无锡成博科技发展有限公司 一种口服给与用吸附剂及其制备方法和应用
CN106238023A (zh) * 2016-08-22 2016-12-21 成都欧赛医疗器械有限公司 一种用于改善血液净化材料表面生物相容性的包膜方法

Similar Documents

Publication Publication Date Title
TWI319985B (en) Adsorbent for oral administration, agent for treating or preventing renal disease, and agent for treating or preventing liver disease
CA1139673A (en) Spherical particles of activated carbon suitable for use as an antidotal pharmaceutical composition
EP2628483B1 (en) Medical adsorbent and method for producing same
US4822765A (en) Process for treating activated carbon with aqueous ammonia
WO2023151350A1 (zh) 交联玉米多孔淀粉负载姜黄素的复合凝胶微球及其制备方法
JP2007197338A (ja) 医薬用吸着剤
Lee et al. Preparation of spherical encapsulation of activated carbons and their adsorption capacity of typical uremic toxins
TWI341732B (en) Adsorbent for oral administration,agent for treating or preventing renal disease, and
JP5424177B2 (ja) 経口投与用吸着剤
TWI644686B (zh) Oral poison adsorbent and preparation method thereof
WO2018227448A1 (zh) 口服毒物吸附剂及其制造方法
JP2016014057A (ja) 経口投与用医薬用吸着剤の製造方法
CN114209851A (zh) 一种姜黄素-氧化硅纳米载药体系及其制备方法和应用
Balabushevich et al. Fabrication and properties of pH-sensitive nanostructured polyelectrolyte microparticles loaded with insulin
CN116440883B (zh) 一种血液灌流器填料的制备方法
CN116162210B (zh) 一种Fe3O4表面接枝羧甲基壳聚糖红景天苷分子印迹缓释剂的制备方法及应用
CN114832142B (zh) 一种壳聚糖复合敷料及其制备方法
CN113768899B (zh) 一种胶体果胶铋胶囊及制备方法
RU2159624C1 (ru) Средство для коррекции микробиоценоза
TW201722402A (zh) 口服毒物吸附劑
CN114344284A (zh) 一种蛛丝载药口腔缓释膜的制备方法及应用
Peng et al. Facile fabrication of diatomite biosilica-based nasal drug delivery vehicle for enhanced treatment of allergic rhinitis
CN116082697A (zh) 基于酵母的纳米纤维气凝胶及其在铅中毒排铅中的用途
US20170290856A1 (en) Oral adsorbent and method for producing oral adsorbent
RU2201755C2 (ru) Способ лечения уремического синдрома

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17913856

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17913856

Country of ref document: EP

Kind code of ref document: A1